Serum autoantibodies and the risk of cancer in systemic sclerosis over time

De Santis, Maria; Tonutti, Antonio; Motta, Francesca; Rodolfi, Stefano; Isailovic, Natasa; Selmi, Carlo

doi:10.1002/art.42701

Arthritis & Rheumatology

2023

DOI: 10.1002/art.42701

|View full text |Cite

Serum autoantibodies and the risk of cancer in systemic sclerosis over time

Maria De Santis,

Antonio Tonutti,

Francesca Motta

et al.

Abstract: 2. Yaciuk JC, Pan Y, Schwarz K, et al. Defective selection of thymic regulatory T cells accompanies autoimmunity and pulmonary infiltrates in Tcra-deficient mice double transgenic for human La/Sjogren's syndrome-B and human La-specific TCR.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Autoantibodies as putative biomarkers and triggers of cell dysfunctions in systemic sclerosis

Rosa,

Romano,

Fioretto

et al. 2024

Current Opinion in Rheumatology

View full text Add to dashboard Cite

Purpose of review Antinuclear autoantibodies represent a serological hallmark of systemic sclerosis (SSc), with anticentromere, antitopoisomerase-I, and anti-RNA polymerase III antibodies routinely assessed for diagnosis, clinical subset classification, and prognosis. In addition, an increasing number of autoantibodies have been demonstrated to play a pathogenic role by mediating different SSc manifestations. This review aims to give an overview on autoantibodies as putative biomarkers in SSc and discuss their possible pathogenic role as triggers of cell dysfunctions. Recent findings Over the years, different autoantibodies have been proposed as biomarkers aiding in diagnosis, disease subtype classification, disease progression prediction, organ involvement, as well as in understanding treatment response. Increasing literature also indicates functional autoantibodies as direct contributors to SSc pathogenesis by exerting agonistic or antagonistic activities on their specific cognate targets. Summary In SSc, search and validation of novel autoantibodies with higher diagnostic specificity and more accurate predictive values are increasingly needed for early diagnosis and specific follow-up, and to define the best therapeutic option according to different disease subsets. Moreover, since autoantibodies are also emerging as functional pathogenic players, a better unraveling of their possible pathomechanisms becomes essential to identify new targets and develop promising therapeutic agents able to neutralize their effects.

show abstract

Autoantibodies as putative biomarkers and triggers of cell dysfunctions in systemic sclerosis

Rosa,

Romano,

Fioretto

et al. 2024

Current Opinion in Rheumatology

View full text Add to dashboard Cite

show abstract

Autoantibodies, cutaneous subset and immunosuppressants contribute to the cancer risk in systemic sclerosis

Tonutti,

Motta,

Isailovic

et al. 2024

RMD Open

View full text Add to dashboard Cite

ObjectiveSystemic sclerosis (SSc) is associated with an increased risk of cancer. We aimed to assess the prevalence of cancer in our cohort and to explore possible associations with clinical, immunological and treatment characteristics.MethodsOur retrospective monocentric cohort study of patients with SSc recorded prevalent and incident cases of malignancy, including those diagnosed within 3 years of the SSc onset (defined as cancer-associated scleroderma) and sought associations with the clinical characteristics and the serum autoantibody profiling performed using RNA and protein immunoprecipitation, Western-blot, immunoblot and ELISA at the time of SSc diagnosis, prior to any specific treatment.ResultsAmong 290 patients with SSc, the overall prevalence of cancer was 20%, with 8% of cases being cancer-associated scleroderma. Both conditions were more frequent in elderly patients and in patients with positive anti-Ro52 or anti-U3-RNP. Cancer-associated scleroderma was significantly more prevalent among patients negative for both anti-centromere (ACA) and anti-topoisomerase-1 (TOPO1) antibodies, especially in the case of diffuse SSc. Immunosuppressants were not significantly associated with cancer. Patients triple negative for ACA, TOPO1 and anti-RNA polymerase III antibodies had a significantly higher risk of breast cancer.ConclusionsCancer surveillance should be particularly careful in patients with diffuse SSc, increased age at disease onset and without classical SSc-related autoantibodies.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Serum autoantibodies and the risk of cancer in systemic sclerosis over time

Abstract: 2. Yaciuk JC, Pan Y, Schwarz K, et al. Defective selection of thymic regulatory T cells accompanies autoimmunity and pulmonary infiltrates in Tcra-deficient mice double transgenic for human La/Sjogren's syndrome-B and human La-specific TCR.

Cited by 2 publications

References 5 publications

Autoantibodies as putative biomarkers and triggers of cell dysfunctions in systemic sclerosis

Autoantibodies as putative biomarkers and triggers of cell dysfunctions in systemic sclerosis

Autoantibodies, cutaneous subset and immunosuppressants contribute to the cancer risk in systemic sclerosis

Contact Info

Product

Resources

About